Literature DB >> 18617647

Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.

Lance A Johnson1, Michael K Altenburg, Rosemary L Walzem, Lori T Scanga, Nobuyo Maeda.   

Abstract

OBJECTIVE: To examine the effects of apoB100 structure, specifically a mutation in the LDLr binding region, on the production of LDL and development of atherosclerosis in vivo. METHODS AND
RESULTS: Ldlr(-/-)Apobec1(-/-) mice lacking the LDLR and apoB editing enzyme accumulated LDL in plasma and developed severe atherosclerosis when they had wild-type apoB100. In marked contrast, in Ldlr(-/-)Apobec1(-/-) mice carrying the Apob100-beta mutation, in the 2 putative LDLR-binding domains of apoB prevented both LDL accumulation and atherosclerosis. Intestinal absorption of lipids and triglyceride secretion from the liver were not affected. However, the VLDL particles with apoB100-beta were larger in volume by about 70%, and carried approximately four times as much apoE per particle. ApoB100-beta synthesis rate in the primary hepatocytes was normal, but its intracellular degradation was enhanced. Additionally, mutant apoB100 VLDL cleared from the circulation more quickly in vivo through apoE-LRP-mediated mechanism than VLDL with wild-type apoB100. In contrast, uptake of the 2 VLDL by macrophages were not different.
CONCLUSIONS: While conformational change to apoB100 during conversion of VLDL to LDL exposes LDLR binding domains and facilitates LDLR-mediated lipoprotein clearance, it may also inhibit LRP-mediated VLDL uptake and contribute to LDL accumulation in familial hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617647      PMCID: PMC5268125          DOI: 10.1161/ATVBAHA.108.169680

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

1.  Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B.

Authors:  Donald L Gillian-Daniel; Paul W Bates; Angie Tebon; Alan D Attie
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  The unstirred water layer as a site of control of apolipoprotein B secretion.

Authors:  K J Williams; R W Brocia; E A Fisher
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

5.  The molecular mechanism for the genetic disorder familial defective apolipoprotein B100.

Authors:  J Borén; U Ekström; B Agren; P Nilsson-Ehle; T L Innerarity
Journal:  J Biol Chem       Date:  2000-12-13       Impact factor: 5.157

6.  Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins.

Authors:  J Greeve; I Altkemper; J H Dieterich; H Greten; E Windler
Journal:  J Lipid Res       Date:  1993-08       Impact factor: 5.922

7.  Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion.

Authors:  R A Borchardt; R A Davis
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

8.  Hepatic secretion of small lipoprotein particles in apobec-1-/- mice is regulated by the LDL receptor.

Authors:  Fatiha Nassir; Yan Xie; Bruce W Patterson; Jianyang Luo; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2004-05-16       Impact factor: 5.922

9.  Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice.

Authors:  Michael Altenburg; Jose Arbones-Mainar; Lance Johnson; Jennifer Wilder; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-27       Impact factor: 8.311

10.  The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver.

Authors:  Sofia L Larsson; Josefin Skogsberg; Johan Björkegren
Journal:  J Biol Chem       Date:  2003-10-28       Impact factor: 5.157

View more
  7 in total

1.  Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4.

Authors:  Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  FASEB J       Date:  2010-05-25       Impact factor: 5.191

2.  Development of apolipoprotein E-deficient mice.

Authors:  Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09       Impact factor: 8.311

Review 3.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

4.  Enhanced hepatic apoA-I secretion and peripheral efflux of cholesterol and phospholipid in CD36 null mice.

Authors:  Pin Yue; Zhouji Chen; Fatiha Nassir; Carlos Bernal-Mizrachi; Brian Finck; Salman Azhar; Nada A Abumrad
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

5.  Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammation.

Authors:  Lance A Johnson; Hyung-Suk Kim; Melissa J Knudson; C Taylor Nipp; Xianwen Yi; Nobuyo Maeda
Journal:  J Lipid Res       Date:  2012-11-30       Impact factor: 5.922

6.  Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.

Authors:  Lance A Johnson; Jose M Arbones-Mainar; Raymond G Fox; Avani A Pendse; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  Diabetes       Date:  2011-08-01       Impact factor: 9.461

7.  Hepatic and Aortic Arch Expression and Serum Levels of Syndecan-1 in ApoE-/- Mice.

Authors:  Elena I Leonova; Elena S Sadovnikova; Elvira R Shaykhutdinova; Oxana V Galzitskaya; Arkady N Murashev; Alexandr S Solonin
Journal:  Open Biochem J       Date:  2017-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.